NCT04614467Phase 2Terminated

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

Study sponsor: Lisata Therapeutics, Inc. · LSTA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-09-28Actual

Enrollment · participants34Actual

Source updated2026-05-04Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-27 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Change From Baseline in Angina ~~Frequency~~ Measure: Change From Baseline in CCS Angina Class Measure: Change From Baseline in Total Exercise Time Measure: Change From Baseline in Health-related Quality of Life (HRQoL)

+ After

Measure: Change From Baseline in Number of Angina Attacks Per Week Measure: Change From Baseline in CCS Angina Class Measure: Change From Baseline in Total Exercise Time Measure: Change From Baseline in Health-related Quality of Life (HRQoL)

Check registry source

Study details

Conditions studied

Coronary Microvascular Dysfunction; Coronary Microvascular Disease; Microvascular Coronary Artery Disease

Treatments or interventions studied

CLBS16Biological
PlaceboBiological

Primary outcomes · main study measures

Read the study measures

measure: Change From Baseline in Number of Angina Attacks Per Week; timeFrame: Baseline to Month 3; measure: Change From Baseline in CCS Angina Class; description: This measure assesses the change in the Canadian Cardiovascular Society angina class scale. CCS angina class was assessed at baseline and again at 3 months and reported as the mean difference. CCS classes are as follows (negative change indicates an improvement): Class 0: No angina with ordinary activity Class I: Angina only with strenuous, prolonged, or rapid exertion Class II: Angina with slight limitations of ordinary activity (e.g., walking uphill, climbing stairs) Class III: Angina with marked limitations of ordinary activity (e.g., walking one to two blocks, climbing one flight of stairs) Class IV: Angina at rest or with minimal exertion; timeFrame: Baseline to 3 months; measure: Change From Baseline in Total Exercise Time; timeFrame: Baseline to 6 months; measure: Change From Baseline in Health-related Quality of Life (HRQoL); description: Seattle Angina Questionnaire (SAQ) Scoring is 0 to 100 with higher numbers better; timeFrame: Baseline to 3 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history